MX2017012679A - Polipeptidos que contienen dominios de union de novo y usos de los mismos. - Google Patents
Polipeptidos que contienen dominios de union de novo y usos de los mismos.Info
- Publication number
- MX2017012679A MX2017012679A MX2017012679A MX2017012679A MX2017012679A MX 2017012679 A MX2017012679 A MX 2017012679A MX 2017012679 A MX2017012679 A MX 2017012679A MX 2017012679 A MX2017012679 A MX 2017012679A MX 2017012679 A MX2017012679 A MX 2017012679A
- Authority
- MX
- Mexico
- Prior art keywords
- dbdpp
- binding domain
- domain containing
- libraries
- containing polypeptides
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 238000001261 affinity purification Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464413—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464419—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Abstract
En este documento se proporcionan polipéptidos que contienen dominios de unión de novo (DBDpp) que se unen específicamente a un objetivo de interés. También seproporcionan ácidos nucleicos que codifican los DBDpp y vectores y células hospedantes que contienen los ácidos nucleicos. Las colecciones de DBDpp, los métodos para producir y examinar estas colecciones y los DBDpp identificados de estas colecciones y exámenes también están comprendidos. Se proporcionan adicionalmente métodos de elaboración y uso de los DBDpp. Estos usos incluyen, sin limitación, purificación por afinidad y aplicaciones de diagnóstico y terapéuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562143772P | 2015-04-06 | 2015-04-06 | |
PCT/US2016/025868 WO2016164305A1 (en) | 2015-04-06 | 2016-04-04 | De novo binding domain containing polypeptides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017012679A true MX2017012679A (es) | 2018-02-09 |
Family
ID=57072017
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017012679A MX2017012679A (es) | 2015-04-06 | 2016-04-04 | Polipeptidos que contienen dominios de union de novo y usos de los mismos. |
MX2021013161A MX2021013161A (es) | 2015-04-06 | 2017-10-02 | Polipeptidos que contienen dominios de union de novo y usos de los mismos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021013161A MX2021013161A (es) | 2015-04-06 | 2017-10-02 | Polipeptidos que contienen dominios de union de novo y usos de los mismos. |
Country Status (27)
Country | Link |
---|---|
US (8) | US10662248B2 (es) |
EP (3) | EP3280433B1 (es) |
JP (4) | JP6871232B2 (es) |
KR (1) | KR20180012747A (es) |
CN (3) | CN107921090A (es) |
AU (3) | AU2016246426B2 (es) |
BR (1) | BR112017021308A2 (es) |
CA (2) | CA2981616A1 (es) |
CY (1) | CY1124453T1 (es) |
DK (2) | DK3280432T3 (es) |
EA (1) | EA201792226A1 (es) |
ES (2) | ES2901273T3 (es) |
HK (2) | HK1249421A1 (es) |
HR (1) | HRP20210498T1 (es) |
HU (1) | HUE054435T2 (es) |
IL (2) | IL254907B (es) |
LT (1) | LT3280432T (es) |
MX (2) | MX2017012679A (es) |
NZ (1) | NZ736022A (es) |
PH (1) | PH12017501834A1 (es) |
PL (1) | PL3280432T3 (es) |
PT (1) | PT3280432T (es) |
RS (1) | RS61907B1 (es) |
SG (2) | SG10202007987QA (es) |
SI (1) | SI3280432T1 (es) |
WO (3) | WO2016164308A1 (es) |
ZA (1) | ZA201706875B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107921090A (zh) * | 2015-04-06 | 2018-04-17 | 苏伯多曼有限责任公司 | 含有从头结合结构域的多肽及其用途 |
WO2018075586A1 (en) * | 2016-10-18 | 2018-04-26 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof |
CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
US20200024353A1 (en) * | 2017-02-10 | 2020-01-23 | Dragonfly Therapeutics, Inc. | Proteins binding psma, nkg2d and cd16 |
AU2018219348A1 (en) * | 2017-02-10 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Proteins binding BCMA, NKG2D and CD16 |
CA3054079A1 (en) | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
EP3621635A4 (en) | 2017-05-10 | 2021-02-24 | Wellstat Immuno Therapeutics, LLC | WRAPPED VIRUS RESISTANT TO INACTIVATION OF THE CANCER TREATMENT COMPLEMENT |
CN107216395B (zh) * | 2017-07-03 | 2018-07-20 | 上海科医联创生物科技有限公司 | 一种tm4sf1特异性嵌合抗原受体及其应用 |
WO2019060750A2 (en) * | 2017-09-23 | 2019-03-28 | Memorial Sloan Kettering Cancer Center | A33 ANTIBODY COMPOSITIONS AND METHODS OF USE IN RADIOIMMUNOTHERAPY |
TWI701259B (zh) | 2017-11-09 | 2020-08-11 | 大陸商上海懷越生物科技有限公司 | 4﹘1bb抗體及其製備方法和應用 |
US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
CA3082406A1 (en) * | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
KR20200087176A (ko) | 2017-11-14 | 2020-07-20 | 아르셀엑스, 인크. | 다기능성 면역 세포 요법 |
PE20220278A1 (es) | 2018-02-08 | 2022-02-25 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d |
WO2019178518A1 (en) * | 2018-03-16 | 2019-09-19 | The Regents Of The University Of California | Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells |
GB201903479D0 (en) * | 2019-03-14 | 2019-05-01 | Univ Oxford Innovation Ltd | Polypeptide with enchanced rate of spontaneous isopeptide bond formation with it's peptide tag partner and uses thereof |
WO2020205836A1 (en) * | 2019-04-02 | 2020-10-08 | Eli Lilly And Company | Methods of selecting and detecting binding peptides |
CN111848733B (zh) * | 2019-04-30 | 2024-03-12 | 上海细胞治疗集团有限公司 | 一种多肽组合物及疫苗 |
WO2020242988A2 (en) * | 2019-05-24 | 2020-12-03 | Avitide, Inc. | Affinity agents |
EP3976083A4 (en) | 2019-05-31 | 2023-07-12 | iBio, Inc. | MACHINE LEARNING BASED DEVICE FOR THE DEVELOPMENT OF MESO-SCALE PEPTIDES, AND METHOD AND SYSTEM THEREOF |
EP4010031A1 (en) | 2019-08-06 | 2022-06-15 | L.E.A.F Holdings Group LLC | Processes of preparing polyglutamated antifolates and uses of their compositions |
JPWO2021100585A1 (es) * | 2019-11-20 | 2021-05-27 | ||
WO2021115333A1 (zh) * | 2019-12-10 | 2021-06-17 | 苏州克睿基因生物科技有限公司 | 一种融合蛋白及表达此蛋白的工程化免疫细胞及其应用 |
CN111560391B (zh) * | 2020-05-21 | 2022-02-11 | 北京大学 | 一种蛋白质异质索烃的生物合成方法 |
CN111732635B (zh) * | 2020-06-22 | 2022-03-22 | 中国医学科学院基础医学研究所 | 与cd123蛋白特异性结合的多肽、多肽复合物、共递送***及其制备方法与应用 |
AU2021299573A1 (en) * | 2020-07-03 | 2023-02-23 | The Trustees Of Columbia University In The City Of New York | Polyfunctional orthogonal protein chimeras |
US20240067955A1 (en) * | 2021-01-20 | 2024-02-29 | Coding Bio Limited | Methods for high throughput screening of chimeric antigen receptors |
US11827716B2 (en) | 2021-11-15 | 2023-11-28 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
WO2023159136A2 (en) * | 2022-02-18 | 2023-08-24 | Dana-Farber Cancer Institute, Inc. | Epitope engineering of cell-surface receptors |
WO2023177851A1 (en) * | 2022-03-17 | 2023-09-21 | Singular Immune, Inc | Composition and method of use recombinant fusion protein to generate car-immune cells |
WO2023212602A2 (en) * | 2022-04-27 | 2023-11-02 | Board Of Regents, The University Of Texas System | Cd30 hinge and/or transmembrane domain-based chimeric antigen receptors |
CN115028689B (zh) * | 2022-06-15 | 2023-05-30 | 浙江东方基因生物制品股份有限公司 | 特异性检测hpv6和hpv11的双特异性检测试剂盒 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
CA1319120C (en) | 1985-04-01 | 1993-06-15 | John Henry Kenten | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
AU4474497A (en) | 1996-10-08 | 1998-05-05 | U-Bisys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
US7763258B2 (en) | 1997-05-20 | 2010-07-27 | The Trustees Of The University Of Pennsylvania | Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins |
DE19802708A1 (de) | 1998-01-24 | 1999-07-29 | Hoechst Marion Roussel De Gmbh | Verwendung von hydroxypyridon-haltigen Puderzubereitungen zur Behandlung von Unterschenkel- und Druckgeschwüren |
US20020155604A1 (en) | 1998-02-19 | 2002-10-24 | Jeffrey A. Ledbetter | Compositions and methods for regulating lymphocyte activation |
US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
EP2067788B1 (en) | 1999-05-18 | 2015-07-22 | Dyax Corp. | Fab fragment libraries and methods for their use |
EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
JP2003518075A (ja) | 1999-12-24 | 2003-06-03 | ジェネンテック・インコーポレーテッド | 生理活性化合物の消失半減期延長のための方法及び組成物 |
AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
AU8822601A (en) | 2000-07-31 | 2002-02-13 | Biolex Inc | Expression of biologically active polypeptides in duckweed |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
KR101001243B1 (ko) | 2001-12-27 | 2010-12-17 | 글리코파이, 인크. | 포유동물-유형 탄수화물 구조의 설계 방법 |
EP1474161A4 (en) | 2002-01-16 | 2005-06-29 | Zyomyx Inc | TRANSGENIC BINDING PROTEINS |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US7314974B2 (en) | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
EP1485492B1 (en) | 2002-03-19 | 2011-12-21 | Stichting Dienst Landbouwkundig Onderzoek | Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta(1,4)-n-acetylglucosaminyltransferase iii) expression in plants |
PT1534830E (pt) | 2002-09-06 | 2011-01-31 | Isogenica Ltd | Biblioteca de expressão de péptidos in vitro |
ES2347325T3 (es) | 2002-09-12 | 2010-10-28 | Greenovation Biotech Gmbh | Metodo de produccion de proteinas. |
AU2003294912B2 (en) | 2002-12-20 | 2009-06-04 | Greenovation Biotech Gmbh | Production of heterologous glycosylated proteins in bryophyte cells |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
WO2005044982A2 (en) | 2003-09-05 | 2005-05-19 | Oregon Health & Science University | Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells |
DK1737971T3 (da) * | 2004-01-20 | 2017-11-13 | Merus Nv | Blandinger af bindingsproteiner |
DK1776384T3 (da) | 2004-08-04 | 2013-09-02 | Mentrik Biotech Llc | VARIANT-Fc-REGIONER |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
EP1896503B1 (en) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
EP1933883B1 (en) | 2005-08-03 | 2015-10-07 | Rq Bioscience, Inc. | Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases |
DK2359834T5 (en) | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
GB0907251D0 (en) * | 2009-04-28 | 2009-06-10 | Univ Leiden | Coplymers |
US10023657B2 (en) * | 2010-10-01 | 2018-07-17 | Ludwig Institute For Cancer Research Ltd. | Reversible protein multimers, methods for their production and use |
CN106220739A (zh) | 2010-12-09 | 2016-12-14 | 宾夕法尼亚大学董事会 | 嵌合抗原受体‑修饰的t细胞治疗癌症的用途 |
WO2014028776A1 (en) | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
WO2014046278A1 (ja) * | 2012-09-21 | 2014-03-27 | 株式会社カネカ | アフィニティー分離マトリックス用タンパク質リガンド |
WO2014159947A1 (en) * | 2013-03-14 | 2014-10-02 | University Of Washington Through Its Center For Commercialization | High affinity digoxigenin binding proteins |
WO2014138805A1 (en) | 2013-03-14 | 2014-09-18 | Csl Limited | Anti il-3r alpha agents and uses thereof |
US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
WO2016154621A1 (en) | 2015-03-26 | 2016-09-29 | The California Institute For Biomedical Research | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF |
CN107921090A (zh) | 2015-04-06 | 2018-04-17 | 苏伯多曼有限责任公司 | 含有从头结合结构域的多肽及其用途 |
KR20160126340A (ko) | 2015-04-23 | 2016-11-02 | 삼성전자주식회사 | 3중-나선 다발 단백질 및 이의 용도 |
KR20200087176A (ko) | 2017-11-14 | 2020-07-20 | 아르셀엑스, 인크. | 다기능성 면역 세포 요법 |
CA3082406A1 (en) | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
-
2016
- 2016-04-04 CN CN201680032015.3A patent/CN107921090A/zh active Pending
- 2016-04-04 EP EP16777109.6A patent/EP3280433B1/en active Active
- 2016-04-04 RS RS20210529A patent/RS61907B1/sr unknown
- 2016-04-04 HU HUE16777107A patent/HUE054435T2/hu unknown
- 2016-04-04 ES ES16777109T patent/ES2901273T3/es active Active
- 2016-04-04 BR BR112017021308-7A patent/BR112017021308A2/pt active Search and Examination
- 2016-04-04 DK DK16777107.0T patent/DK3280432T3/da active
- 2016-04-04 LT LTEP16777107.0T patent/LT3280432T/lt unknown
- 2016-04-04 SG SG10202007987QA patent/SG10202007987QA/en unknown
- 2016-04-04 EP EP21155053.8A patent/EP3903804A1/en active Pending
- 2016-04-04 EA EA201792226A patent/EA201792226A1/ru unknown
- 2016-04-04 CA CA2981616A patent/CA2981616A1/en active Pending
- 2016-04-04 EP EP16777107.0A patent/EP3280432B8/en active Active
- 2016-04-04 JP JP2018503725A patent/JP6871232B2/ja active Active
- 2016-04-04 ES ES16777107T patent/ES2866202T3/es active Active
- 2016-04-04 SG SG11201708257UA patent/SG11201708257UA/en unknown
- 2016-04-04 PT PT167771070T patent/PT3280432T/pt unknown
- 2016-04-04 CN CN201680032016.8A patent/CN107708720A/zh active Pending
- 2016-04-04 JP JP2018503726A patent/JP6873101B2/ja active Active
- 2016-04-04 MX MX2017012679A patent/MX2017012679A/es unknown
- 2016-04-04 NZ NZ736022A patent/NZ736022A/en unknown
- 2016-04-04 SI SI201631199T patent/SI3280432T1/sl unknown
- 2016-04-04 DK DK16777109.6T patent/DK3280433T3/da active
- 2016-04-04 AU AU2016246426A patent/AU2016246426B2/en active Active
- 2016-04-04 KR KR1020177031697A patent/KR20180012747A/ko not_active Application Discontinuation
- 2016-04-04 US US15/564,325 patent/US10662248B2/en active Active
- 2016-04-04 PL PL16777107T patent/PL3280432T3/pl unknown
- 2016-04-04 CN CN202210256708.8A patent/CN115160438A/zh active Pending
- 2016-04-04 WO PCT/US2016/025880 patent/WO2016164308A1/en active Application Filing
- 2016-04-04 CA CA2981711A patent/CA2981711A1/en active Pending
- 2016-04-04 US US15/564,319 patent/US10647775B2/en active Active
- 2016-04-04 WO PCT/US2016/025868 patent/WO2016164305A1/en active Application Filing
- 2016-04-05 WO PCT/US2016/026054 patent/WO2016164369A2/en active Application Filing
- 2016-04-05 US US15/564,430 patent/US20180209983A1/en not_active Abandoned
-
2017
- 2017-10-02 MX MX2021013161A patent/MX2021013161A/es unknown
- 2017-10-06 IL IL254907A patent/IL254907B/en active IP Right Grant
- 2017-10-06 PH PH12017501834A patent/PH12017501834A1/en unknown
- 2017-10-11 ZA ZA2017/06875A patent/ZA201706875B/en unknown
-
2018
- 2018-07-11 HK HK18109015.2A patent/HK1249421A1/zh unknown
- 2018-07-11 HK HK18109016.1A patent/HK1249422A1/zh unknown
-
2020
- 2020-01-24 US US16/751,730 patent/US20200362046A1/en not_active Abandoned
- 2020-03-13 US US16/817,755 patent/US11008397B2/en active Active
- 2020-03-20 US US16/824,809 patent/US20210002381A1/en active Pending
-
2021
- 2021-02-09 AU AU2021200810A patent/AU2021200810B2/en active Active
- 2021-03-29 HR HRP20210498TT patent/HRP20210498T1/hr unknown
- 2021-04-13 US US17/228,817 patent/US20210230288A1/en active Pending
- 2021-04-15 JP JP2021068754A patent/JP7244567B2/ja active Active
- 2021-04-27 IL IL282704A patent/IL282704A/en unknown
- 2021-06-03 CY CY20211100483T patent/CY1124453T1/el unknown
-
2022
- 2022-12-22 US US18/145,169 patent/US20240043550A1/en active Pending
-
2023
- 2023-01-23 JP JP2023007753A patent/JP2023052563A/ja not_active Withdrawn
- 2023-08-22 AU AU2023219820A patent/AU2023219820A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501834A1 (en) | De novo binding domain containing polypeptides and uses thereof | |
IL272797A (en) | DNA with a modified closed end | |
EP3649147A4 (en) | POLYNUCLEOTIDES FOR THE ENCODING OF IMMUNSTIMULATORY FUSION MOLECULES AND USES THEREOF | |
PH12018500906A1 (en) | Antibodies specifically binding pd-1 and their uses | |
WO2019224718A3 (en) | Psma binding agents and uses thereof | |
MX2023003125A (es) | Proteinas multiespecificas de union al antigeno. | |
EP3585431A4 (en) | BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES | |
MX2017003847A (es) | Proteinas biespecificas activables por proteasas. | |
WO2017106684A3 (en) | Antibodies specifically binding hla-dr and their uses | |
PH12020550240A1 (en) | D-domain containing polypeptides and uses thereof | |
EA201991383A1 (ru) | Антитела против ctla-4 и способы их применения | |
MX2019008359A (es) | Cadena j modificada. | |
MX2021008367A (es) | Constructos de anticuerpos para cdh19 y cd3. | |
WO2015120058A3 (en) | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity | |
EP4276116A3 (en) | Bispecific antibody constructs for cdh3 and cd3 | |
WO2018081592A3 (en) | Compositions and methods for the production of compounds | |
EP3717505A4 (en) | GENENICALLY MODIFIED DNA-BINDING PROTEINS | |
EP4059961A3 (en) | Anti-tau constructs | |
MX2018005399A (es) | Nuevo polipeptido con afinidad por pd-l1. | |
EP3543335A3 (en) | Soluble intein fusion proteins and methods for purifying biomolecules | |
MX2020003093A (es) | Anticuerpos anti-cd19 novedosos. | |
MX2019013124A (es) | Proteinas de fusion de inhibidor de tripsina urinaria (uti). | |
WO2015166105A3 (en) | Ion channel modulators and uses thereof | |
PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
BR112015019719A2 (pt) | Proteínas melhoradas de ligação ao tnf |